PATENT CLAIM ANALYSIS

Application Number: 16118535
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-01
Patent Classification: ["424", "443000"]

Abstract:
A pharmaceutical composition for administration of Dabigatran zetexilate through the mucous membranes of the oral cavity, characterized in that the composition comprises a therapeutically effective amount of Dabigatran etexilate and a solubilizer for Dabigatran etixilate selected from at least one of a water soluble derivative of tocopherol and a polymeric derivative of sorbitan. The composition may be in the form of solid oral film. The composition may be suitable for dropwise administration. A method of manufacturing the film composition is also included.

Claim (Index 2):
The composition according to  claim 1 , comprising:\n 10 to 40% (w/w) of Dabigatran etexilate; 10 to 50% (w/w) of water-soluble cellulose; 1 to 10% (w/w) of a tocopherol polyethylene glycol succinate (TPGS); 1 to 10% (w/w) of a polyoxoethylene sorbitan monooleate; and 1 to 10% (w/w) each of polyethylene glycol, glycerol and propylene glycol.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 96.0
- Lexical Diversity: 1.67308
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15185888', '13636310', '14714195', '14080505', '15308014']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.724604248717755
- 35 USC 102 Novelty (BERT): 0.5082717784918973
- Combined Prediction Score: 0.7029710016951692
- Mean Citation Score: 243.38857400000003
- Max Citation Score: 260.60684
- Similarity Product: 169.41527004671337

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test